BMS sues AstraZeneca for infringing cancer treatment drug

26-01-2023

Liz Hockley

BMS sues AstraZeneca for infringing cancer treatment drug

US pharma giant says competitor’s drug Imjudo violates two patents | BMS’ blockbuster was first to use checkpoint inhibitors, says complaint.


BMS, AstraZeneca, Yervoy, ipilimumab, patents, cancer, treatment, Imjudo, tremelimumab, checkpoint inhibitors

LSIPR